global health has allotted 61,500 equity shares under its employee stock option scheme, following approval by the Nomination & Remuneration Committee on April 22, 2026. The shares were issued to the GHL Employees Welfare Trust under Part-A of the GHL-Employee Long Term Share Based Incentive Plan 2024, also known as the GHL Employees Stock Option Scheme 2024. The allotment was made pursuant to Regulation 30 of SEBI Listing Regulations.

The equity shares carry a face value of Rs. 2 each and were issued at a premium of Rs. 1,080 per share, resulting in an issue price of Rs. 1,082 per share. Following this allotment, the company's paid-up share capital has increased from Rs. 53,75,80,764 to Rs. 53,77,03,764. The total number of equity shares now stands at 26,88,51,882, up from the previous 26,87,90,382 shares.

Key Allotment Details

The shares allotted to the GHL Employees Welfare Trust will be transferred to eligible employees' Demat accounts in accordance with the provisions of the scheme. The newly issued shares carry distinctive numbers ranging from 26,87,90,383 to 26,88,51,882.

Post-Allotment Capital Structure

The allotment has resulted in a modest increase in the company's equity base. The total issued share capital after this issue stands at Rs. 53,77,03,764. All equity shares allotted pursuant to the exercise of stock options rank pari-passu with the existing equity shares of the company in all respects, ensuring equal rights and privileges for shareholders.

The company had previously filed necessary statements with both BSE and NSE in March and April 2025, with respective case numbers for ESOP and ESPS filings. The shares are listed on both Bombay Stock Exchange (Scrip Code: 543654, Symbol: MEDANTA) and National Stock Exchange of India Limited.

Global Health has received a revised target price from HSBC, which has raised its price target to ₹1,120 from the earlier ₹1,100 while maintaining a Hold rating on the stock. The brokerage's outlook reflects expectations of steady performance in the upcoming quarter.

Q4FY26 Performance Outlook

HSBC anticipates a stable performance for Global Health in Q4FY26, driven by several key operational factors. The brokerage highlights an expected pickup in elective procedures, which typically contribute significantly to hospital revenues and margins.

Expansion and Margin Dynamics

The company continues its capital expenditure expansion program, which is expected to support long-term growth prospects. However, HSBC notes that new units are likely to create near-term margin pressure as these facilities ramp up operations and achieve optimal utilization levels.

Operational Performance

Despite the margin headwinds from new units, HSBC observes continued healthy operating trends across Global Health's existing hospital network. This suggests that the company's established facilities are maintaining their operational efficiency and patient volumes.

The brokerage's revised target price reflects a balanced view of the company's growth initiatives and operational challenges, with the modest upward revision indicating cautious optimism about the healthcare provider's prospects.